Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tifcemalimab - Shanghai Junshi Biosciences

Next Previous
X
Search
Drug Profile

Tifcemalimab - Shanghai Junshi Biosciences

Alternative Names: Icatolimab; JS-004; TAB-004 - Shanghai Junshi Biosciences; TAB004 - Junshi Biosciences

Latest Information Update: 18 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Junshi Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action BTLA protein antagonists; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hodgkin's disease; Small cell lung cancer
  • Phase II Renal cell carcinoma
  • Phase I/II Head and neck cancer; Nasopharyngeal cancer
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 12 Dec 2024 RenJi Hospital plans a phase II trial for Renal cell carcinoma (Unresectable/Inoperable, Late-stage disease, Second-line therapy or greater, Metastatic disease, Combination therapy) in China (IV, Infusion) (NCT06730932)
  • 19 Sep 2024 Henan Provincial People's Hospital plans a phase II trial for Squamous cell cancer (Late-stag disease, Neoadjuvant therapy, Combination therapy) (IV, Infusion) (NCT06588335)
  • 01 Jun 2024 Phase-II clinical trials in Renal cell carcinoma (Second-line therapy or greater, Metastatic disease, Combination therapy, Recurrent) in China (IV) (NCT06690697)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top